Ordspono™ (odronextamab) approved in the european union for the treatment of relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma

Approval of ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large b-cell lymphoma, including in the post-car-t setting

REGN Ratings Summary

REGN Quant Ranking